Singapore markets open in 2 hours 8 minutes

NLS Pharmaceutics AG (NLSP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1988-0.0062 (-3.02%)
At close: 04:00PM EDT
0.1994 +0.00 (+0.30%)
After hours: 07:38PM EDT

NLS Pharmaceutics AG

The Circle 6
Zurich 8058
Switzerland
41 44 512 21 50
https://nlspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Alexander Zwyer M.B.A.CEO & Director917kN/A1969
Dr. Eric Konofal M.D., Ph.D.Co-Founder & Chief Scientific Officer179kN/A1967
Ms. Elena Thyen-PighinCFO and Head of Finance & Human Resources61kN/A1972
Dr. George Apostol M.D.Chief Medical Officer and Global Head of Research & Development390kN/A1973
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Corporate governance

NLS Pharmaceutics AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.